Lead Candidate

🌟 Celebrating 4 years of partnership 🌟 We're excited to share a special video testimonial from our long-standing partners, INCOG BioPharma Services ⚙️ At Lead Candidate, we take great pride in the strong partnership we've built with INCOG, founded on trust, shared values, and a mutual commitment to our goals. It's truly a privilege to have played a part in INCOG's growth journey. 📽️ In this video, hear firsthand from Cory Lewis, CEO and Doug Dayhoff, CFO as they share why they continue to trust us as their talent partner of choice. (P.S. You can find the full-length video from our trip to INCOG here: https://lnkd.in/e7BzWhXX) #Partnership #Testimonial #TalentPartner

We had planned to post a nice 'Merry Christmas' message today as people start winding down for the holiday season, but we just couldn't wait to announce these brand new roles! Lead Candidate are proud to be partnered with a leading European CRO who are looking to grow their commercial team with three key appointments across Europe and the US. Following extensive growth over the last 18 months, this is an opportunity to join a commercial team supported with significant investment and resources. These highly motivated individuals will play a crucial part in developing the drug discovery services business to drive the next chapter of growth. Does this sound like the opportunity for you? Check out the jobs and apply using the links below: ➡️ BDD - Northern Europe & UK: https://lnkd.in/gYkRHRGU ➡️ BDD - Southern Europe: https://lnkd.in/g5mxqMwQ ➡️ BDD - US: https://lnkd.in/gMXJjSYr #CRO #BusinessDevelopment #BusinessDevelopmentDirector

When it comes to investing in your team, can you afford to sit on the fence? Making the decision to hire is a big step, but with 2025 around the corner, it's important to get thinking about the coming year. Having the right people on your team is crucial to laying the foundation for success. Take action, choose growth, and invest in your team. Lead Candidate are a global talent partner fuelling growth for CDMOs, CROs, and Pharma Services. Interested in how we could help? Get in touch ⬇️ 🌐 Find out more about what we do here: https://lnkd.in/dYZC9U4 📲 Book a discovery call here: https://lnkd.in/di8RNERy

Novo Holdings has closed its $16.5 billion acquisition of Catalent Pharma Solutions 🤝 ✅ This comes after the deal received the greenlight from the Federal Trade Commission and European Commission 🏢 Novo Holdings plans to sell three of the CDMO giant's fill-finish sites to GLP-1 maker Novo Nordisk, drawing criticism from those worried it will limit competition. Read more on the deal below ⬇️ #Catalent #NovoNordisk #PharmaNews #CDMO

Can you spot the differences? (HINT: there are 4) 👀 Back in July, we celebrated Lead Candidate's 3rd birthday with a team photoshoot on our steps. Just 5 months later, those same steps look a bit more crowded! These photos are a testament to the incredible year we've had as we head into 2025. Alongside helping our partners build their teams, we've been fortunate enough to grow our own. By this time next year, we might need to find some bigger steps... 📸 Thank you to the wonderful Sarah Deane for capturing these shots over the year! #TalentPartner #TalentAcquisition #Team

Thinking ahead to 2025? Get your headcount plan for the coming year accurate with our strategies for success ⬇️ Helping businesses in the CDMO, CRO, and Pharma Services space get their talent agenda on track is what we're all about - and that means supporting more than just hiring. If you need some support with your headcount plan for 2025, get in touch! 📧 [email protected] 📲 Book a discovery call here: https://lnkd.in/di8RNERy #CDMO #CRO #Pharma #TalentPartner

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing and jettisoning less profitable areas of its operations. 👉 The restructuring strategy aims to reorganise its CDMO business, reshape its operating model, work to "elevate" manufacturing and engineering, and expand its production footprint. 💊 Notably, Lonza also intends to hive off its capsules and health ingredients (CHI) business "at the appropriate time." 💬 Dr. Wolfgang Wienand, the company's new CEO, said: "Since I joined Lonza in July 2024, I have spent time reviewing the business with the leadership team and identifying areas with unique strengths as well as areas where we can optimize value. The strategy reflects our ambition to become a pure-play CDMO business." Read more about Lonza's restructuring plans below ⬇️ #CDMO #Biologics #Lonza

🚨 Recruitment Myths Unmasked! 🚨 We've all heard them! Swipe to see 7 common recruitment myths get well and truly debunked ➡️ Are there any myths we missed? 👀 At Lead Candidate, we're committed to transparency and making sure that everyone in the hiring value chain has a dedicated partner on their side. So, if you're a CDMO, CRO, or pharma service provider (or someone looking for your next role within these) we're here for you! 🌟 Interested in how we're changing the recruitment landscape for the better? 🌐 Find out more about what we do here: https://lnkd.in/dYZC9U4 📲 Or Book a discovery call here: https://lnkd.in/di8RNERy #CDMO #CRO #Pharma

Cellipont Bioservices, announces partnership with Xiogenix, to access cutting-edge fill/finish system! 🤝 Cellipoint, a cell therapy CDMO, will have access to Xiogenix's Ares x20 fill/finish system, designed for cell and gene therapy production. The cutting-edge system offers precise temperature control, automated formulation, high-throughput, and the ability to process multiple containers in fewer than five minutes. 💬 "This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices," said Darren Head, CEO of Cellipont Bioservices. "We are committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing. Through this collaboration with Xiogenix, we offer our clients access to advanced fill-and-finish system, enhancing our service offerings and delivering superior solutions." 💬 "We are thrilled to partner with Cellipont Bioservices to bring ourAres™ X20 fill and finish system to a broader range of clients," said Rachel Bahr, CEO of Xiogenix. "This collaboration aligns with our mission to provide innovative solutions that enhance the efficiency and reliability of biopharmaceutical manufacturing. We look forward to seeing the positive impact this partnership will have on the industry." #CDMO #CGT #CellTherapy

💰 The global CRO market is projected to hit almost $63 billion by 2030, according to a new report from market researcher, Research and Markets. 📈 The CRO market is projected to grow an average of 7.39% annually from 2025 to 2030. The global clinical trial site network market is also predicted to grow at a similar rate, hitting $13.76 billion globally by 2030. 🌏 The Asia-Pacific region is especially primed for growth, according to the reports, because of more local CRO activity and more trials being outsourced to the area. In 2024, the region held 46.4% of the global CRO market share. ➡️ Read more here: https://lnkd.in/exGjkwVj #CRO #ClinicalTrials #ContractResearch